"Designing Growth Strategies is in our DNA"

Oncology Biosimilars Market Size, Share & Industry Analysis, By Drug Class (Anti-HER2 Monoclonal Antibodies, Anti-VEGF Monoclonal Antibodies, Anti-CD20, and Immune Checkpoint Inhibitors), By Product (Trastuzumab, Bevacizumab, Rituximab, Pertuzumab, and Pembrolizumab), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Non-Hodgkin's Lymphoma, and Melanoma), By Age Group (Pediatric and Adults), By Route of Administration (Intravenous and Subcutaneous), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Retail Pharmacies), and Regional Forecast, 2026-2034

Last Updated: August 10, 2026 | Format: PDF | Report ID: FBI100578

 

Buy Now

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Key Disease Indications, By Key Regions, Countries
    2. Pipeline Analysis, By Key Regions
    3. Overview of Regulatory Scenario, By Key Regions/Countries
    4. New Product Launches, By Key Players
    5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  5. Global Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class    
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product        
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of the Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Celltrion, Inc.
      2. Amgen Inc.
      3. Pfizer Inc.
      4. Biocon Biologics Limited
      5. Samsung Bioepis Co., Ltd.
      6. Sandoz Group AG
      7. Shanghai Henlius Biotech, Inc.
      8. Teva Pharmaceutical Industries Ltd.
      9. Organon & Co.
      10. Accord Healthcare Limited
      11. Fresenius Kabi AG 
      12. Amneal Pharmaceuticals, Inc.
      13. Dr. Reddy’s Laboratories Ltd.
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Key Disease Indications, By Key Regions, Countries
    2. Pipeline Analysis, By Key Regions
    3. Overview of Regulatory Scenario, By Key Regions/Countries
    4. New Product Launches, By Key Players
    5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  5. Global Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class   
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product       
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class    
      1. Anti-HER2 Monoclonal Antibodies
      2. Anti-VEGF Monoclonal Antibodies
      3. Anti-CD20 Monoclonal Antibodies
      4. Immune Checkpoint Inhibitor Biosimilars
      5. Other Therapeutic Monoclonal Antibodies
      6. Others
    2. Market Analysis, Insights and Forecast – By Product        
      1. Trastuzumab
      2. Bevacizumab
      3. Rituximab
      4. Pertuzumab
      5. Pembrolizumab
      6. Nivolumab
      7. Ipilimumab
      8. Others
    3. Market Analysis, Insights and Forecast – By Application
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Non-Hodgkin’s Lymphoma
      5. Chronic Lymphocytic Leukemia
      6. Gastric & Gastroesophageal Junction Cancer
      7. Melanoma
      8. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous
      3. Others
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of the Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Celltrion, Inc.
      2. Amgen Inc.
      3. Pfizer Inc.
      4. Biocon Biologics Limited
      5. Samsung Bioepis Co., Ltd.
      6. Sandoz Group AG
      7. Shanghai Henlius Biotech, Inc.
      8. Teva Pharmaceutical Industries Ltd.
      9. Organon & Co.
      10. Accord Healthcare Limited
      11. Fresenius Kabi AG 
      12. Amneal Pharmaceuticals, Inc.
      13. Dr. Reddy’s Laboratories Ltd.
Read Less

Figure 1: Global Oncology Biosimilars Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2: Global Oncology Biosimilars Market Value Share (%), by Drug Class, 2025 & 2034

Figure 3: Global Oncology Biosimilars Market Value Share (%), by Product, 2025 & 2034

Figure 4: Global Oncology Biosimilars Market Value Share (%), by Application, 2025 & 2034

Figure 5: Global Oncology Biosimilars Market Value Share (%), by Age Group, 2025 & 2034

Figure 6: Global Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025 & 2034

Figure 7: Global Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 8: Global Oncology Biosimilars Market Value Share (%), by Region, 2025 & 2034

Figure 9: North America Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 10: North America Oncology Biosimilars Market Value Share (%), by Drug Class, 2025

Figure 11: North America Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034

Figure 12: North America Oncology Biosimilars Market Value Share (%), by Product, 2025

Figure 13: North America Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034

Figure 14: North America Oncology Biosimilars Market Value Share (%), by Application 2025

Figure 15: North America Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034

Figure 16: North America Oncology Biosimilars Market Value Share (%), by Age Group, 2025

Figure 17: North America Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 18: North America Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025

Figure 19: North America Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 20: North America Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 21: North America Oncology Biosimilars Market Value (USD billion), by Country, 2025 & 2034

Figure 22: North America Oncology Biosimilars Market Value Share (%), by Country, 2025

Figure 23: Europe Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 24: Europe Oncology Biosimilars Market Value Share (%), by Drug Class, 2025

Figure 25: Europe Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034

Figure 26: Europe Oncology Biosimilars Market Value Share (%), by Product, 2025

Figure 27: Europe Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034

Figure 28: Europe Oncology Biosimilars Market Value Share (%), by Application 2025

Figure 29: Europe Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034

Figure 30: Europe Oncology Biosimilars Market Value Share (%), by Age Group, 2025

Figure 31: Europe Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 32: Europe Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025

Figure 33: Europe Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 34: Europe Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 35: Europe Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 36: Europe Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025

Figure 37: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 38: Asia Pacific Oncology Biosimilars Market Value Share (%), by Drug Class, 2025

Figure 39: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034

Figure 40: Asia Pacific Oncology Biosimilars Market Value Share (%), by Product, 2025

Figure 41: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034

Figure 42: Asia Pacific Oncology Biosimilars Market Value Share (%), by Application 2025

Figure 43: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034

Figure 44: Asia Pacific Oncology Biosimilars Market Value Share (%), by Age Group, 2025

Figure 45: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 46: Asia Pacific Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025

Figure 47: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 48: Asia Pacific Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 49: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 50: Asia Pacific Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025

Figure 51: Latin America Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 52: Latin America Oncology Biosimilars Market Value Share (%), by Drug Class, 2025

Figure 53: Latin America Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034

Figure 54: Latin America Oncology Biosimilars Market Value Share (%), by Product, 2025

Figure 55: Latin America Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034

Figure 56: Latin America Oncology Biosimilars Market Value Share (%), by Application 2025

Figure 57: Latin America Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034

Figure 58: Latin America Oncology Biosimilars Market Value Share (%), by Age Group, 2025

Figure 59: Latin America Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 60: Latin America Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025

Figure 61: Latin America Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 62: Latin America Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 63: Latin America Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 64: Latin America Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025

Figure 65: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 66: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Drug Class, 2025

Figure 67: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034

Figure 68: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Product, 2025

Figure 69: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034

Figure 70: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Application 2025

Figure 71: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034

Figure 72: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Age Group, 2025

Figure 73: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 74: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025

Figure 75: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 76: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 77: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 78: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025

Figure 79: Global Oncology Biosimilars Market Share (%), by Company, 2025

Table 1: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 2: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 3: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021–2034

Table 4: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 5: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 6: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 7: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 8: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 9: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 10: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021–2034

Table 11: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 12: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 13: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 14: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country, 2021-2034

Table 15: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 16: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 17:  Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021–2034

Table 18: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 19: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 20: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 21: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 22: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 23: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 24: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021–2034

Table 25: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 26: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 27: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 28: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 29: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 30: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 31: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021–2034

Table 32: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 33: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 34: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 35: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 36: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 37: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 38: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021–2034

Table 39: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 40: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 41: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 42: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Oncology Biosimilars Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Customize Now
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann